Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.33

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€4.08M

Enterprise Value€29.19

Total Cash (Recent Filing)€6.93M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Therapeutic Pipeline (sickle Cell Disease)A concentrated R&D strategy targeting sickle cell disease addresses a clear, durable unmet medical need. This focused pipeline can attract strategic partners, grants, and specialist investors, and supports long-term value creation if clinical progress continues, independent of short-term market moves.

Very Low Financial LeverageZero reported debt reduces fixed financial obligations and bankruptcy risk during extended clinical development cycles. This structural balance-sheet characteristic provides flexibility to pursue extended R&D timelines and negotiate financing or partnerships without imminent debt service pressures.

Positive Equity Base After RecapitalizationDespite prior volatility, a positive equity balance in 2025 indicates the company has executed financings or recapitalizations to sustain operations. That ability to access capital markets or investor support is a durable operational capability essential for pre-revenue biotech continuity through clinical milestones.

Bears Say

Persistent And Rising Cash BurnSteady negative operating and free cash flows, with worsening burn to -SEK 18.1m in 2025, create ongoing funding needs. Over a multi‑month horizon this structural cash deficit heightens dilution and execution risk unless substantial financing or partnership activity secures runway.

No Revenue VisibilityBeing pre-revenue through 2025 leaves the company dependent on external capital and milestone events. Without recurring sales or clear near-term commercialization pathways, sustainable profitability remains uncertain, making long-term operations contingent on continued financing or strategic partnerships.

Very Limited Internal ResourcesAn employee count of two implies heavy reliance on contractors, CROs, or partners for clinical and regulatory work. This structural resourcing constraint raises execution risk for complex clinical programs and can slow responsiveness to operational challenges over the coming months.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.33 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €4.08M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 30 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.